Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.55 |
| ▸ | DRD3 | P35462 | 2/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | DRD5 | P21918 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2061606 | 0.91 | DRD2 (0.54) | DRD2DRD3DRD1DRD5CHRM2 | |
| SCHEMBL2061271 | 0.87 | DRD2 (0.50) | DRD2DRD3DRD1DRD5CHRM2 | |
| SCHEMBL29396439 | 0.86 | DRD2 (0.49) | DRD2DRD3DRD1DRD5CHRM2 | |
| SCHEMBL268506 | 0.86 | DRD2 (0.49) | DRD2DRD3DRD1DRD5CHRM2 | |
| SCHEMBL2641069 | 0.85 | DRD2 (0.50) | DRD2DRD3DRD1DRD5CHRM2 | |
| SCHEMBL8600453 | 0.82 | PNMT (0.57) | DRD2DRD3DRD1DRD5CHRM2 | |
| SCHEMBL20460376 | 0.81 | CYP2A6 (0.43) | DRD2DRD3DRD1DRD5CYP2A6 | |
| SCHEMBL2061100 | 0.81 | DRD2 (0.47) | DRD2DRD3DRD1DRD5CHRM2 | |
| SCHEMBL19133719 | 0.81 | DRD2 (0.58) | DRD2DRD3DRD1DRD5CHRM2 | |
| Ammonia Solution, Strong SCHEMBL7667257 | 0.79 | DRD2 (0.56) | DRD2DRD3DRD1DRD5CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2623593-B1 | NOVEL AMINOTRANSFERASE AND GENE ENCODING SAME, AND USE OF THE AMINOTRANSFERASE AND THE GENE | KANEKA CORP (JP) | 2017-07-12 | — | — | EP | claimed |
| EP-2684953-B1 | MODIFIED AMINOTRANSFERASE, GENE THEREOF, AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUND USING SAME | KANEKA CORP (JP) | 2017-06-28 | — | — | EP | claimed |
| EP-2623595-B1 | NOVEL TRANSAMINASE SHOWING HIGH ACTIVITY FOR GLUTAMIC ACID, GENE ENCODING SAME, AND METHOD FOR UTILIZATION THEREOF | KANEKA CORP (JP) | 2016-11-02 | — | — | EP | claimed |
| US-9481870-B2 | Nucleic acid encoding a polypeptide having aminotransferase activity, vectors and host cells comprising the nucleic acid | KANEKA CORPORATION (JP) | 2016-11-01 | — | — | US | claimed |
| CN-103534353-B | Modification type aminopherase, its gene and utilize their manufacture method of optical activity amino-compound | 株式会社钟化 | 2016-08-17 | — | — | CN | claimed |
| US-9029113-B2 | Modified aminotransferase, gene thereof, and method for producing optically active amino compound using same | KANEKA CORPORATION (JP) | 2015-05-12 | — | — | US | claimed |
| CN-103534353-A | Modified aminotransferase, gene thereof, and method for producing optically active amino compound using same | KANEKA CORP | 2014-01-22 | — | — | CN | claimed |
| EP-2684953-A1 | MODIFIED AMINOTRANSFERASE, GENE THEREOF, AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUND USING SAME | Kaneka Corporation (JP) | 2014-01-15 | — | — | EP | claimed |
| US-20140004575-A1 | MODIFIED AMINOTRANSFERASE, GENE THEREOF, AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUND USING SAME | KANEKA CORPORATION (JP) | 2014-01-02 | — | — | US | claimed |
| US-20130210092-A1 | Novel Transaminase, Gene Encoding the Same, and Method Using Them | KANEKA CORPORATION (JP) | 2013-08-15 | — | — | US | claimed |
| EP-2623595-A1 | NOVEL TRANSAMINASE SHOWING HIGH ACTIVITY FOR GLUTAMIC ACID, GENE ENCODING SAME, AND METHOD FOR UTILIZATION THEREOF | Kaneka Corporation (JP) | 2013-08-07 | — | — | EP | claimed |
| EP-2623593-A1 | NOVEL AMINOTRANSFERASE AND GENE ENCODING SAME, AND USE OF THE AMINOTRANSFERASE AND THE GENE | Kaneka Corporation (JP) | 2013-08-07 | — | — | EP | claimed |
| US-20130196389-A1 | NOVEL TRANSAMINASE EXHIBITING HIGH ACTIVITY FOR GLUTAMIC ACID, GENE ENCODING SAME, AND METHOD FOR USING THEM | KANEKA CORPORATION (JP) | 2013-08-01 | — | — | US | claimed |
| EP-1889907-A1 | NOVEL AMINO GROUP TRANSFERASE, GENE ENCODING THE SAME AND METHOD OF USING THE SAME | Kaneka Corporation (JP) | 2008-02-20 | — | — | EP | claimed |
| US-7074770-B1 | Method of DNA vaccination | SMITHKLINE BEECHAM CORPORATION (US) | 2006-07-11 | — | — | US | claimed |
| EP-1107785-A1 | METHOD OF DNA VACCINATION | GLAXO GROUP LIMITED (GB) | 2001-06-20 | — | — | EP | claimed |
| WO-2000012121-A1 | METHOD OF DNA VACCINATION | GLAXO GROUP LIMITED (GB) | 2000-03-09 | — | — | WO | claimed |
| US-12209092-B2 | Inhibitors of GLI1 as therapeutic agents | NEW YORK UNIVERSITY (US) | 2025-01-28 | — | — | US | disclosed |
| EP-0041488-A1 | Therapeutically useful tetralin derivatives | Arvidsson, Folke Lars-Erik (SE) | 1981-12-09 | — | — | EP | disclosed |
| US-4239903-A | ANTISPASMODIC AGENTS | DAIICHI SEIYAKU CO., LTD. (JP) | 1980-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209092-B2 | Inhibitors of GLI1 as therapeutic agents | GLI1, GLI2, SHH | DRD2 4742/4885DRD3 4784/4885DRD1 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.